ASK PHARM(SZ:002755) 智通财经网·2025-10-19 08:55Core Viewpoint - The company announced that its subsidiary, Jiangsu Osaikang Pharmaceutical Co., Ltd., presented data on a novel cMET inhibitor, ASKC202, in combination with Lapatinib, at the European Society for Medical Oncology (ESMO) annual meeting in Berlin on October 18, 2025, focusing on patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and have MET amplification/overexpression [1] Group 1 - ASK202 in combination with Lapatinib demonstrated good tolerability and safety in patients with NSCLC who had previously failed EGFR-TKI treatment [1] - The treatment showed promising efficacy signals, including a high tumor response rate and prolonged duration of response [1] - A Phase III confirmatory clinical trial for ASK202 in combination with Lapatinib is currently underway [1]